Tissue-plasminogen activator effects on the phenotype of splenic myeloid cells in acute inflammation

Célia Seillier,Léonie Lesec,Pauline Hélie,Charlotte Marie,Denis Vivien,Fabian Docagne,Brigitte Le Mauff,Olivier Toutirais

DOI: https://doi.org/10.1186/s12950-024-00375-0

2024-02-15

Journal of Inflammation

Abstract:Tissue-plasminogen activator (tPA) is a serine protease well known for its fibrinolytic function. Recent studies indicate that tPA could also modulate inflammation via plasmin generation and/or by receptor mediated signalling in vitro. However, the contribution of tPA in inflammatory processes in vivo has not been fully addressed. Therefore, using tPA-deficient mice, we have analysed the effect of lipopolysaccharide (LPS) challenge on the phenotype of myeloid cells including neutrophils, macrophages and dendritic cells (DCs) in spleen. We found that LPS treatment upregulated the frequency of major histocompatibility class two (MHCII + ) macrophages but also, paradoxically, induced a deep downregulation of MHCII molecule level on macrophages and on conventional dendritic cells 2 (cDC2). Expression level of the CD11b integrin, known as a tPA receptor, was upregulated by LPS on MHCII + macrophages and cDC2, suggesting that tPA effects could be amplified during inflammation. In tPA −/− mice under inflammatory conditions, expression of costimulatory CD86 molecules on MHCII + macrophages was decreased compared to WT mice, while in steady state the expression of MHCII molecules was higher on macrophages. Finally, we reported that tPA deficiency slightly modified the phenotype of DCs and T cells in acute inflammatory conditions. Overall, our findings indicate that in vivo, LPS injection had an unexpectedly bimodal effect on MHCII expression on macrophages and DCs that consequently might affect adaptive immunity. tPA could also participate in the regulation of the T cell response by modulating the levels of CD86 and MHCII molecules on macrophages.

immunology